Works matching AU Kumar, Shaji

Results: 400
    1
    2
    3
    4
    5
    6
    7
    8

    Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).

    Published in:
    2017
    By:
    • Hubbard, Joleen;
    • Mahoney, Michelle;
    • Loui, William;
    • Roberts, Lewis;
    • Smyrk, Thomas;
    • Gatalica, Zoran;
    • Borad, Mitesh;
    • Kumar, Shaji;
    • Alberts, Steven;
    • Hubbard, Joleen M;
    • Mahoney, Michelle R;
    • Loui, William S;
    • Roberts, Lewis R;
    • Smyrk, Thomas C;
    • Alberts, Steven R
    Publication type:
    journal article
    9
    10

    Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies: Guideline From the College of American Pathologists in Collaboration With the American Association for Clinical Chemistry and the American Society for Clinical Pathology.

    Published in:
    Archives of Pathology & Laboratory Medicine, 2022, v. 146, n. 5, p. 575, doi. 10.5858/arpa.2020-0794-CP
    By:
    • Keren, David F.;
    • Bocsi, Gregary;
    • Billman, Brooke L.;
    • Etzell, Joan;
    • Faix, James D.;
    • Kumar, Shaji;
    • Lipe, Brea;
    • McCudden, Christopher;
    • Montgomery, Roberta;
    • Murray, David L.;
    • Rai, Alex J.;
    • Cuyegkeng Redondo, Teresita;
    • Souter, Lesley;
    • Ventura, Christina B.;
    • Ansari, Mohammad Qasim
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17

    Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition.

    Published in:
    Annals of Medicine, 2017, v. 49, n. 7, p. 545, doi. 10.1080/07853890.2017.1304649
    By:
    • Muchtar, Eli;
    • Dispenzieri, Angela;
    • Lacy, Martha Q.;
    • Buadi, Francis K.;
    • Kapoor, Prashant;
    • Hayman, Suzanne R.;
    • Gonsalves, Wilson;
    • Warsame, Rahma;
    • Kourelis, Taxiarchis V.;
    • Chakraborty, Rajshekhar;
    • Russell, Stephen;
    • Lust, John A.;
    • Lin, Yi;
    • Go, Ronald S.;
    • Zeldenrust, Steven;
    • Rajkumar, S. Vincent;
    • Dingli, David;
    • Leung, Nelson;
    • Kyle, Robert A.;
    • Kumar, Shaji K.
    Publication type:
    Article
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28

    Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma.

    Published in:
    British Journal of Haematology, 2022, v. 199, n. 1, p. 95, doi. 10.1111/bjh.18298
    By:
    • Abeykoon, Jithma P.;
    • Vaxman, Julia;
    • Patel, Sanjay V.;
    • Kumar, Shaji;
    • Malave, Gabriella C.;
    • Young, Kimberly S.;
    • Ailawadhi, Sikander;
    • Larsen, Jeremy T.;
    • Dispenzieri, Angela;
    • Muchtar, Eli;
    • Gonsalves, Wilson I.;
    • Kourelis, Taxiarchis;
    • Leung, Nelson;
    • Warsame, Rahma;
    • Go, Ronald S.;
    • Bergsagel, Leif;
    • Lacy, Martha Q.;
    • Rajkumar, S. Vincent;
    • Gertz, Morie A.;
    • Kapoor, Prashant
    Publication type:
    Article
    29
    30

    Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial.

    Published in:
    EJHaem, 2023, v. 4, n. 4, p. 995, doi. 10.1002/jha2.759
    By:
    • Richardson, Paul G.;
    • Facon, Thierry;
    • Venner, Christopher P.;
    • Bahlis, Nizar J.;
    • Offner, Fritz;
    • White, Darrell;
    • Karlin, Lionel;
    • Benboubker, Lotfi;
    • Voog, Eric;
    • Yoon, Sung‐Soo;
    • Suzuki, Kenshi;
    • Shibayama, Hirohiko;
    • Zhang, Xiaoquan;
    • Villarreal, Miguel;
    • Twumasi‐Ankrah, Philip;
    • Labotka, Richard;
    • Rifkin, Robert M.;
    • Lonial, Sagar;
    • Kumar, Shaji K.;
    • Rajkumar, S. Vincent
    Publication type:
    Article
    31

    Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance).

    Published in:
    Neuro-Oncology Advances, 2022, v. 4, n. 1, p. 1, doi. 10.1093/noajnl/vdac041
    By:
    • Galanis, Evanthia;
    • Anderson, S. Keith;
    • Twohy, Erin;
    • Butowski, Nicholas A.;
    • Hormigo, Adilia;
    • Schiff, David;
    • Omuro, Antonio;
    • Jaeckle, Kurt A.;
    • Kumar, Shaji;
    • Kaufmann, Timothy J.;
    • Geyer, Susan;
    • Kumthekar, Priya U.;
    • Campian, Jian;
    • Giannini, Caterina;
    • Buckner, Jan C.;
    • Wen, Patrick Y.
    Publication type:
    Article
    32

    Comparison of Laboratory Data at Initial Diagnosis of Multiple Myeloma Between Black Africans, African Americans and White patients.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 12, p. 863, doi. 10.1016/j.clml.2024.07.010
    By:
    • Essiaw, Lambert A.;
    • Bolarinwa, Abiola;
    • Hongwei Tang;
    • Kudowor, Gertrude;
    • Shivaram, Suganti;
    • Sharma, Neeraj;
    • Linden, Michael A.;
    • Buadi, Francis K.;
    • Rajkumar, S. Vincent;
    • Kumar, Shaji;
    • Dei-Adomakoh, Yvonne;
    • Cook, Joselle M.;
    • Baughn, Linda B.;
    • Paemka, Lily
    Publication type:
    Article
    33

    Comparison of Laboratory Data at Initial Diagnosis of Multiple Myeloma Between Black Africans, African Americans and White patients.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 12, p. 863, doi. 10.1016/j.clml.2024.07.010
    By:
    • Essiaw, Lambert A.;
    • Bolarinwa, Abiola;
    • Hongwei Tang;
    • Kudowor, Gertrude;
    • Shivaram, Suganti;
    • Sharma, Neeraj;
    • Linden, Michael A.;
    • Buadi, Francis K.;
    • Rajkumar, S. Vincent;
    • Kumar, Shaji;
    • Dei-Adomakoh, Yvonne;
    • Cook, Joselle M.;
    • Baughn, Linda B.;
    • Paemka, Lily
    Publication type:
    Article
    34

    Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 3, p. e104, doi. 10.1016/j.clml.2023.11.008
    By:
    • Goldman-Mazur, Sarah;
    • Visram, Alissa;
    • Rajkumar, S. Vincent;
    • Kapoor, Prashant;
    • Dispenzieri, Angela;
    • Lacy, Martha Q.;
    • Gertz, Morie A.;
    • Buadi, Francis K.;
    • Hayman, Suzanne R.;
    • Dingli, David;
    • Kourelis, Taxiarchis;
    • Gonsalves, Wilson;
    • Warsame, Rahma;
    • Muchtar, Eli;
    • Leung, Nelson;
    • Kyle, Robert A.;
    • Kumar, Shaji K.
    Publication type:
    Article
    35
    36

    Disease Monitoring In Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 4, p. 244, doi. 10.1016/j.clml.2023.01.005
    By:
    • Hillengass, Jens;
    • Martin, Tom;
    • Puig, Noemi;
    • Paiva, Bruno;
    • Usmani, Saad;
    • Kumar, Shaji;
    • San-Miguel, Jesus
    Publication type:
    Article
    37

    P-201: Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S148, doi. 10.1016/S2152-2650(21)02328-4
    By:
    • Malek, Ehsan;
    • Kansagra, Ankit;
    • Costa, Luciano;
    • Usmani, Saad Z.;
    • Vij, Ravi;
    • Shaji Kumar;
    • Godby, Kelly;
    • Bal, Susan;
    • Cornell, Robert;
    • Yubin Kang;
    • Umyarova, Elvira;
    • Giri, Smith;
    • Chhabra, Saurabh;
    • Callander, Natalie S.;
    • Hari, Parameswaran;
    • Liedtke, Michaela
    Publication type:
    Article
    38

    P-140: Monoclonal proteinuria ≥200 mg/24h predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S111, doi. 10.1016/S2152-2650(21)02267-9
    By:
    • Visram, Alissa;
    • Rajkumar, S. Vincent;
    • Kapoor, Prashant;
    • Dispenzieri, Angela;
    • Lacy, Martha;
    • Gertz, Morie;
    • Buadi, Francis;
    • Hayman, Suzanne;
    • Dingli, David;
    • kourelis, Taxiarchis;
    • Gonsalves, Wilson;
    • Warsame, Rahma;
    • Muchtar, Eli;
    • Leung, Nelson;
    • Kyle, Robert;
    • Kumar, Shaji
    Publication type:
    Article
    39
    40

    OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S23, doi. 10.1016/S2152-2650(21)02110-8
    By:
    • Muchtar, Eli;
    • Wisniowski, Brendan;
    • Palladini, Giovanni;
    • Milani, Paolo;
    • Merlini, Giampaolo;
    • Schönland, Stefan;
    • Veelkan, Kaya;
    • Hegenbart, Ute;
    • Dispenzieri, Angela;
    • Kumar, Shaji;
    • Leung, Nelson;
    • Kastritis, Efstathios;
    • Dimopoulos, Meletios-Athanasios;
    • Liedtke, Michaela;
    • Witteles, Ronald;
    • Sanchorawala, Vaishali;
    • Szalat, Raphael;
    • Landau, Heather;
    • Lentzsch, Suzanne;
    • Bladé, J
    Publication type:
    Article
    41

    OAB-037: Assessing the prognostic utility of the Mayo 2018 and IMWG 2020 smoldering multiple myeloma risk stratification scores applied post diagnosis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S24, doi. 10.1016/S2152-2650(21)02111-X
    By:
    • Visram, Alissa;
    • Rajkumar, S. Vincent;
    • Kapoor, Prashant;
    • Dispenzieri, Angela;
    • Lacy, Martha;
    • Gertz, Morie;
    • Buadi, Francis;
    • Hayman, Suzanne;
    • Dingli, David;
    • kourelis, Taxiarchis;
    • Gonsalves, Wilson;
    • Warsame, Rahma;
    • Muchtar, Eli;
    • Leung, Nelson;
    • Kyle, Robert;
    • Kumar, Shaji
    Publication type:
    Article
    42

    OAB-038: Graded cardiac response criteria for AL amyloidosis: the impact of depth of cardiac response on survival.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S24, doi. 10.1016/S2152-2650(21)02112-1
    By:
    • Muchtar, Eli;
    • Dispenzieri, Angela;
    • Wisniowski, Brendan;
    • Palladini, Giovanni;
    • Milani, Paolo;
    • Merlini, Giampaolo;
    • Schönland, Stefan;
    • Veelkan, Kaya;
    • Hegenbart, Ute;
    • Kumar, Shaji;
    • Kastritis, Efstathios;
    • Dimopoulos, Meletios-Athanasios;
    • Liedtke, Michaela;
    • Witteles, Ronald;
    • Sanchorawala, Vaishali;
    • Szalat, Raphael;
    • Landau, Heather;
    • Lentzsch, Suzanne;
    • Coltoff, Alexander;
    • Blade, Joan
    Publication type:
    Article
    43

    OAB-034: Evaluating the impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis: subanalyses from the ANDROMEDA study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S22, doi. 10.1016/S2152-2650(21)02108-X
    By:
    • Kumar, Shaji;
    • Dispenzieri, Angela;
    • Bhutani, Divaya;
    • Gertz, Morie;
    • Wechalekar, Ashutosh;
    • Palladini, Giovanni;
    • Comenzo, Raymond;
    • Fonseca, Rafael;
    • Jaccard, Arnaud;
    • Kastritis, Efstathios;
    • Schönland, Stefan;
    • Porte, Charles la;
    • Huiling Pei;
    • NamPhuong Tran;
    • Vermeulen, Jessica;
    • Merlini, Giampaolo
    Publication type:
    Article
    44
    45

    OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S1, doi. 10.1016/S2152-2650(21)02075-9
    By:
    • Moreau, Philippe;
    • Facon, Thierry;
    • Kumar, Shaji;
    • Plesner, Torben;
    • Orlowski, Robert Z.;
    • Bahlis, Nizar;
    • Basu, Supratik;
    • Nahi, Hareth;
    • Hulin, Cyrille;
    • Hang Quach;
    • Goldschmidt, Hartmut;
    • O'Dwyer, Michael;
    • Perrot, Aurore;
    • Venner, Christopher;
    • Weisel, Katja;
    • Mace, Joseph R.;
    • Raje, Noopur;
    • Tiab, Mourad;
    • Macro, Margaret;
    • Frenzel, Laurent
    Publication type:
    Article
    46

    MM-431: A Comparison Between Daratumumab and Non-Daratumumab-Based Salvage Regimens Used at First Relapse Post-Lenalidomide Maintenance in Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S444, doi. 10.1016/S2152-2650(21)01987-X
    By:
    • Ho, Matthew;
    • Zanwar, Saurabh;
    • Kapoor, Prashant;
    • Gertz, Morie;
    • Lacy, Martha;
    • Dispenzieri, Angela;
    • Hayman, Suzanne;
    • Dingli, David;
    • Buadi, Francis;
    • Leung, Nelson;
    • Kourelis, Taxiarchis;
    • Warsame, Rahma;
    • Fonder, Amie;
    • Hwa, Lisa;
    • Hobbs, Miriam;
    • Kyle, Robert;
    • Rajkumar, Vincent;
    • Kumar, Shaji
    Publication type:
    Article
    47

    MM-429: Impact of Prolonged Lenalidomide Maintenance (≥3 years) and Outcomes in Patients with Multiple Myeloma Post-Autologous Stem Cell Transplant.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S443, doi. 10.1016/S2152-2650(21)01986-8
    By:
    • Zanwar, Saurabh;
    • Ho, Matthew;
    • Kapoor, Prashant;
    • Gertz, Morie;
    • Lacy, Martha;
    • Dispenzieri, Angela;
    • Hayman, Suzanne;
    • Dingli, David;
    • Buadi, Francis;
    • Leung, Nelson;
    • Kourelis, Taxiarchis;
    • Warsame, Rahma;
    • Fonder, Amie;
    • Yi Hwa;
    • Hobbs, Miriam;
    • Kyle, Robert;
    • Rajkumar, Vincent;
    • Kumar, Shaji
    Publication type:
    Article
    48

    MM-315: Impact of Stratification of Levels of Serum Lactate Dehydrogenase (LDH) at Diagnosis on Overall Survival (OS) in Newly Diagnosed Multiple Myeloma (NDMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S435, doi. 10.1016/S2152-2650(21)01970-4
    By:
    • Evans, Laura A.;
    • Kumar, Shaji K.;
    • Dispenzieri, Angela;
    • Buadi, Francis K.;
    • Dingli, David;
    • Lacy, Martha Q.;
    • Hayman, Suzanne R.;
    • Kapoor, Prashant;
    • Kourelis, Taxiarchis V.;
    • Muchtar, Eli;
    • Go, Ronald S.;
    • Warsame, Rahma;
    • Leung, Nelson;
    • Hobbs, Miriam;
    • Hwa, Y. Lisa;
    • Fonder, Amie;
    • Kyle, Robert A.;
    • Gertz, Morie;
    • Rajkumar, S. Vincent;
    • Gonsalves, Wilson I.
    Publication type:
    Article
    49

    MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S424, doi. 10.1016/S2152-2650(21)01950-9
    By:
    • Orlowski, Robert;
    • Facon, Thierry;
    • Kumar, Shaji;
    • Plesner, Torben;
    • Moreau, Philippe;
    • Bahlis, Nizar;
    • Basu, Supratik;
    • Nahi, Hareth;
    • Hulin, Cyrille;
    • Quach, Hang;
    • Goldschmidt, Hartmut;
    • O'Dwyer, Michael;
    • Perrot, Aurore;
    • Venner, Christopher;
    • Weisel, Katja;
    • Mace, Joseph;
    • Raje, Noopur;
    • Tiab, Mourad;
    • Macro, Margaret;
    • Frenzel, Laurent
    Publication type:
    Article
    50

    Poster: MM-431: A Comparison Between Daratumumab and Non-Daratumumab-Based Salvage Regimens Used at First Relapse Post-Lenalidomide Maintenance in Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S256, doi. 10.1016/S2152-2650(21)01611-6
    By:
    • Ho, Matthew;
    • Zanwar, Saurabh;
    • Kapoor, Prashant;
    • Gertz, Morie;
    • Lacy, Martha;
    • Dispenzieri, Angela;
    • Hayman, Suzanne;
    • Dingli, David;
    • Buadi, Francis;
    • Leung, Nelson;
    • Kourelis, Taxiarchis;
    • Warsame, Rahma;
    • Fonder, Amie;
    • Hwa, Lisa;
    • Hobbs, Miriam;
    • Kyle, Robert;
    • Rajkumar, Vincent;
    • Kumar, Shaji
    Publication type:
    Article